Understanding the genetic risk underlying racial disparities in uterine fibroids

了解子宫肌瘤种族差异背后的遗传风险

• 批准号: 8841609
• 负责人: Digna R Velez Edwards
• 金额: $ 62.65万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-08-12 至 2016-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8841609
• 关键词: Accounting; Admixture; Adult; Affect; African; African American; Age; Age of Onset; Benign; Body mass index; Caucasians; Chromosomes; Code; Complex; Computer Simulation; Computer software; Computerized Medical Record; Cultured Tumor Cells; Custom; DNA; DNA Databases; DNA Resequencing; Data; Disease; Emerging Technologies; Fibroid Tumor; Frequencies; Functional disorder; Genetic; Genetic Markers; Genetic Predisposition to Disease; Genetic Risk; Genome; Genomic Segment; Genotype; Growth; Health; Health Care Costs; Human; Hysterectomy; Image; Incidence; Intervention; Knowledge; Link; Literature; Logistic Regressions; Maps; Menopause; Menstruation; National Institute of Child Health and Human Development; Pain; Participant; Pelvic Pain; Pelvis; Pregnancy Complications; Race; Registries; Relative (related person); Reproductive Health; Research; Research Personnel; Resources; Risk; Role; Sampling; Single Nucleotide Polymorphism; Source; Study Subject; Targeted Resequencing; Testing; Tumor Tissue; Twin Multiple Birth; Twin Studies; United States Agency for Healthcare Research and Quality; United States National Institutes of Health; Uterine Fibroids; Uterine myomectomy; Uterus; Variant; Woman; Women' s Health; Work; case control; cohort; cost effective; design; follow-up; genetic analysis; genetic risk factor; genome wide association study; health disparity; inclusion criteria; interest; meetings; next generation; novel; novel therapeutic intervention; pressure; public health relevance; racial disparity; rare variant; research study; tool; tumor

DESCRIPTION (provided by investigator): Fibroids affect 77% of women by onset of menopause in the U.S. and account for $2.1 billion in healthcare costs each year. Fibroids negatively impact reproductive health causing heavy and painful menses, pelvic pain and pressure, pregnancy complications, and interventions including myomectomy and hysterectomy. Until recently, tumor tissue and cell culture studies investigating fibroid growth have been the primary sources for understanding fibroid pathophysiology. Genetic analysis can provide a powerful and cost effective tool to identify etiological and causal factors, especially since a genetic predisposition to fibroids has already been documented from twin studies. As much as 69% of risk is explained by genetic factors. Racial disparities also support a role for genetics with fibroid risk. African American women have earlier age of onset, more numerous and larger fibroids with a greater lifetime incidence compared to Caucasians. We propose to identify genetic markers for risk of fibroids through a genome-wide association study (GWAS) of African American and Caucasian participants, leveraging ancestral differences to narrow down genomic regions for targeted follow- up analyses. To accomplish this we will take advantage of a unique Vanderbilt resource, the BioVU DNA databank. BioVU currently has over 122,470 adults linked to electronic medical records. From BioVU we have already identified 2,902 African American and Caucasian subjects who meet our stringent inclusion criteria to conduct a GWAS of fibroids, including pelvic imaging. Available imaging is critical, because many women with fibroids are asymptomatic and without imaging, studies may misclassify as many as 51% of women. We have also defined definitive controls who reached menopause without fibroids. We have a strong group of nationally known fibroid researchers who will provide over 10,000 samples for replication. Our first Specific Aim is to conduct a GWAS for association between common single nucleotide polymorphisms (SNPs) and fibroid risk. Using a case-control design we will perform a GWAS in 2,902 (1,451 fibroid cases and 1,451 controls) women from BioVU stratified by African American and Caucasian race. Secondary admixture mapping (AM) analyses will also be performed to identify chromosomal regions of interest to prioritize for replication. Our second Aim is to resequence chromosome regions identified from GWAS and AM to discover rare variants. Finally, in Aim 3 we will replicate SNPs selected from Aim 1 and 2 in independent samples of at least 3,230 fibroid cases and 7,097 controls. We propose an efficient and cost-effective approach to identify genetic risk factors for fibroids, by taking advantage of imaging information and DNA available through BioVU. This study represents the largest GWAS of uterine fibroids and the first among African Americans leveraging emerging technologies and new statistical approaches to conduct this study. Our proposed study will fundamentally change knowledge about fibroids and lay the ground work for breakthroughs in understanding mechanisms of fibroid formation and in identifying novel therapeutic approaches.

描述（由研究者提供）：肌瘤影响美国77%的绝经期妇女，每年造成21亿美元的医疗费用。肌瘤对生殖健康产生负面影响，导致月经严重和疼痛，骨盆疼痛和压力，妊娠并发症，以及子宫肌瘤切除术和子宫切除术等干预措施。直到最近，研究肌瘤生长的肿瘤组织和细胞培养研究一直是了解肌瘤病理生理的主要来源。遗传分析可以提供一个强大的和成本有效的工具，以确定病因和因果因素，特别是因为遗传易感性肌瘤已经从双胞胎研究中记录。多达69%的风险可以用遗传因素来解释。种族差异也支持基因在子宫肌瘤风险中的作用。与白种人相比，非裔美国妇女的肌瘤发病年龄更早，数量更多，体积更大，终生发病率更高。我们建议通过非裔美国人和白种人参与者的全基因组关联研究（GWAS）来确定子宫肌瘤风险的遗传标记，利用祖先差异来缩小基因组区域以进行有针对性的随访分析。为了实现这一目标，我们将利用范德比尔特大学独特的资源，BioVU DNA数据库。BioVU目前有超过122,470名成年人与电子医疗记录相连。从BioVU，我们已经确定了2,902名非裔美国人和白种人受试者，他们符合我们严格的纳入标准，进行肌瘤的GWAS，包括盆腔成像。可用的影像学检查是至关重要的，因为许多患有肌瘤的妇女是无症状的，没有影像学检查，研究可能会错误分类多达51%的妇女。我们还定义了绝经期无肌瘤的确定对照。我们有一个强大的全国知名的肌瘤研究小组，他们将提供超过10,000个样本用于复制。我们的第一个特定目标是对常见单核苷酸多态性（snp）与子宫肌瘤风险之间的关联进行GWAS。采用病例对照设计，我们将对来自BioVU的2,902名女性（1,451名纤维瘤患者和1,451名对照）进行GWAS，这些女性按非裔美国人和高加索人种分层。二级混合作图（AM）分析也将进行，以确定感兴趣的染色体区域优先复制。我们的第二个目标是对从GWAS和AM中鉴定的染色体区域进行重排序，以发现罕见的变异。最后，在Aim 3中，我们将在至少3,230例肌瘤病例和7,097例对照的独立样本中复制从Aim 1和2中选择的snp。我们提出了一种有效和经济的方法来识别子宫肌瘤的遗传风险因素，利用成像信息和DNA可通过BioVU。这项研究代表了最大的子宫肌瘤GWAS，也是非洲裔美国人首次利用新兴技术和新的统计方法进行这项研究。我们提出的研究将从根本上改变对肌瘤的认识，并为了解肌瘤形成机制和确定新的治疗方法奠定基础。